GeneDx names Mark Gardner as President, effective June 15, 2026

GeneDx Holdings Corp.

Mr. Gardner, former Quest Diagnostics SVP, will oversee lab and commercial ops, reporting to CEO Katherine Stueland.
Compensation includes $530K base salary, 65% target bonus, and $2M RSU grant vesting over four years.
Bryan Dechairo transitions to lead product, technology and innovation initiatives.
Gardner previously served as CEO of OmniSeq and held senior roles at Thermo Fisher Scientific and Life Technologies.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Bryan Dechairo

Other

WGS · GeneDx Holdings Corp.

Filed: June 16, 2026, 8:39 AM ET

Following Mr. Gardner’s appointment, Bryan Dechairo will transition into a role focused on leading the Company’s product, technology and innovation initiatives.

Appointed

Mark Gardner

President

WGS · GeneDx Holdings Corp.

Effective: 2026-06-15
Filed: June 16, 2026, 8:39 AM ET

On June 16, 2026, GeneDx Holdings Corp. (the “Company”) announced the appointment of Mark Gardner, age 60, in the role of President, which was effective on June 15, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.65

Bryan Dechairo changed role as other at GeneDx Holdings Corp..

Action: transitioned

Exact text from the filing

Following Mr. Gardner’s appointment, Bryan Dechairo will transition into a role focused on leading the Company’s product, technology and innovation initiatives.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark Gardner was appointed as President at GeneDx Holdings Corp..

Action: appointed
Role: President

Exact text from the filing

On June 16, 2026, GeneDx Holdings Corp. (the “Company”) announced the appointment of Mark Gardner, age 60, in the role of President, which was effective on June 15, 2026.

View on SEC.gov

GeneDx Holdings Corp. filing history →

Source: SEC EDGAR

accession 0001628280-26-043431

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.